In-Hospital Switching Between Clopidogrel and Prasugrel Among Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights Into Contemporary Practice From the National Cardiovascular Data Registry
暂无分享,去创建一个
Deepak L. Bhatt | K. Alexander | C. Granger | R. McNamara | A. Bagai | E. Peterson | J. Curtis | Yongfei Wang | H. Gurm | M. Roe | Tracy Y. Wang | A. Cheema | J. Saucedo | B. Shah
[1] Eric D. Peterson,et al. Early Clopidogrel Versus Prasugrel Use Among Contemporary STEMI and NSTEMI Patients in the US: Insights From the National Cardiovascular Data Registry , 2014, Journal of the American Heart Association.
[2] C. Stefanadis,et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. , 2014, American heart journal.
[3] Antonio Colombo,et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.
[4] M. Effron,et al. Effect on Platelet Reactivity From a Prasugrel Loading Dose After a Clopidogrel Loading Dose Compared With a Prasugrel Loading Dose Alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): A Randomized Controlled Trial , 2013, Circulation. Cardiovascular interventions.
[5] E. Vicaut,et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. , 2013, The New England journal of medicine.
[6] H. Gurm,et al. Contemporary Use of Prasugrel in Clinical Practice: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium , 2013, Circulation. Cardiovascular quality and outcomes.
[7] G. Montalescot,et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. , 2013, JACC. Cardiovascular interventions.
[8] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[9] J. Spertus,et al. Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel , 2013, Circulation. Cardiovascular quality and outcomes.
[10] Jennifer G. Robinson,et al. ACCF/AHA TASK FORCE MEMBERS , 2013 .
[11] D. Faxon. How to Manage Antiplatelet Therapy for Stenting in a Patient Requiring Oral Anticoagulants , 2013, Current Treatment Options in Cardiovascular Medicine.
[12] A. Ferro,et al. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.
[13] J. Messenger,et al. The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. , 2012, Journal of the American College of Cardiology.
[14] Peter K. Smith,et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. , 2012, Journal of the American College of Cardiology.
[15] J. Spertus,et al. Abstract P233: Selecting Antiplatelet Therapy After Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Risks and Benefits of Prasugrel Versus Clopidogrel , 2011, Circulation: Cardiovascular Quality and Outcomes.
[16] E. Antman,et al. Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) , 2011, Circulation.
[17] Judith S. Hochman,et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[18] T. Costigan,et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. , 2010, Journal of the American College of Cardiology.
[19] Irina Proskorovsky,et al. Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention: Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRI , 2010, Circulation.
[20] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[21] Christopher P Cannon,et al. A Call to ACTION (Acute Coronary Treatment and Intervention Outcomes Network): A National Effort to Promote Timely Clinical Feedback and Support Continuous Quality Improvement for Acute Myocardial Infarction , 2009, Circulation. Cardiovascular quality and outcomes.
[22] E. Antman,et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.
[23] E. Antman,et al. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.
[24] P Michael Ho,et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. , 2008, JAMA.
[25] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[26] S. Yusuf,et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.
[27] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[28] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[29] H V Anderson,et al. The American College of Cardiology-National Cardiovascular Data Registry™ (ACC-NCDR™): building a national clinical data repository , 2001 .
[30] K. Hammermeister,et al. The American College of Cardiology National Database: Progress and challenges , 1997 .
[31] K. Hammermeister,et al. The American College of Cardiology National Database: progress and challenges. American College of Cardiology Database Committee. , 1997, Journal of the American College of Cardiology.